Tigermed disclosed its 2026 semi-annual report on August 29. In the first half, total operating revenue reached 3.708 billion yuan, up 14.06 percent year on year, but net profit attributable to the parent company was a loss of 413 million yuan, compared with a profit of 383 million yuan in the same period last year. Non-GAAP net profit was 278 million yuan, up 31.78 percent year on year, and net cash flow from operating activities was 426 million yuan, up 4.2 percent. During the reporting period, total non-recurring gains and losses were negative 691 million yuan, including a negative 481 million yuan change in fair value of financial assets held. As of the close on August 28, the company's price-to-earnings ratio on a trailing twelve-month basis was about 469.64 times, price-to-book ratio about 2.2 times, and price-to-sales ratio about 5.89 times.
TYK Medicines IncHangzhou Tigermed ConsultingNet loss of 413 million yuan in H1 2026, down from profit of 383 million yuan year-on-year.
